Life sciences industry's highest achievers celebrated at prestigious Awards ceremony
PR98518
PERTH, Australia, Oct, 27, 2022 /PRNewswire=KYODO JBN/ --
AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards
-Industry Leadership Award: Professors Steve Wilton AO and Sue Fletcher AO
-Company of the Year: Telix Pharmaceuticals
-Emerging Company of the Year: Fusetec
AusBiotech Life Sciences Legacy Award: Dr Andrew Forrest AO and Nicola Forrest
AO
Biotech's illustrious Industry Excellence Awards were announced today at the
AusBiotech 2022 national conference in Perth – recognising outstanding
contribution and achievement. The AusBiotech and Johnson & Johnson Innovation
Industry Excellence Awards recognise innovative companies and individuals in
Australia's world-class biotechnology, medical technology and healthcare
sectors.
Dr Andrew Forrest AO and Nicola Forrest AO were also awarded the AusBiotech
Life Sciences Legacy Award in recognition of their generous and active support
of medical research and Australian life science innovation.
AusBiotech's Chief Executive Officer, Lorraine Chiroiu, said: "These
prestigeous Awards act as a celebration of the cutting-edge innovation
excellence happening across the country and the extraordinary progress that
these individuals and companies have contributed to the health of Australians,
and to the growth of the sector."
"Congratulations to the recipients, who demonstrate what can be achieved when
innovation, passion, and drive are accompanied by the vision and leadership
needed to bring novel medicines, medical devices and other new technologies to
patients."
Announcing the awards, Ms Kathy Connell, Senior Director, External Innovation
Partnering, ANZ, Johnson & Johnson Innovation, said: "Johnson & Johnson
Innovation is proud to sponsor these awards, and to celebrate and recognise
these exceptional recipients for their commitment to lifescience innovation
excellence. The discovery, development and commercialisation of biomedical
research takes a global effort from diverse ecosystem including scientists,
entrepreneurs, philanthropists and industry partners. This years' awardees
represents contributions from across Australia and we commend their work as
they seek to advance healthcare for humanity around the world."
Dr Forrest said: "We are passionate about finding ethical and sustainable
solutions to a range of issues that impact people and the planet, and we trust
that our commitment and passion, in both our philanthropy work and the
commercial investments we make, is helping to make the world a better place.
"We back Australian research and businesses, as well as partner with people
across the world to share information and accelerate the development of
breakthrough therapies, life-changing products and medical treatments. We are
investing in the future of Australian healthcare innovation in a way that
hasn't been done here before."
More on the 2022 winners
Industry Leadership Award Professor Steve Wilton AO, Director Centre for
Molecular Medicine and Innovative Therapeutics and Foundation Chair in
Molecular Therapies, Murdoch University and Director Perron Institute for
Neurological and Translational Science Perth, WA; and Professor Sue Fletcher
AO, Principal Research Fellow Centre for Molecular Medicine and Innovative
Therapeutics Murdoch University and Chief Scientific Officer, PYC Therapeutics
Perth, WA.
Professors Steve Wilton and Sue Fletcher's collaboration and pioneering
research has resulted in the development of three FDA-approved "exon-skipping"
medicines that overcome specific genetic mutations that cause Duchenne Muscular
Dystrophy (DMD).
Their contribution to Australia's biotech industry spans more than 25 years,
and their work in antisense oligomer-induced exon skipping puts Australia's
medical research into rare diseases and neuromuscular science on the map. All
three medicines (Exondys 51, Vyondys 53 and Amondys 45) were developed at the
Perron Institute for Neurological and Translational Science with The University
of Western Australia and has been commercialised in partnership with US company
Sarepta Therapeutics.
Company of the Year: Telix Pharmaceuticals
Melbourne-headquartered biopharmaceutical company Telix Pharmaceuticals Limited
(Telix) is focused on the development and commercialisation of diagnostic and
therapeutic ('theranostic') radiopharmaceuticals. Founded in 2015, Telix has
moved its lead product Illuccix®, a PSMA PET imaging agent for the detection
and staging of prostate cancer, from academic proof-of-concept to a
commercially-proven product in the space of three short years, with FDA and TGA
approval gained during late 2021 (now reimbursed in both markets), and Health
Canada approval in October 2022.
Commerically launching Illuccix® in the US in April 2022, Telix has since
generated USD$50 million (AUD$73 million) in sales; in addition to Australia,
it now has commerical operations in the US, Europe and Japan. The first patient
was imaged in Australia in September 2022, and US-distribution has rapidly
expanded with a network of more than 150 radiopharmacies nationwide; the US
total addressable market for PSMA PET imaging for prostate cancer is estimated
at USD$1-1.5 billion annually. Telix's has further theranostics for oncology
and rare diseases progressing through the pipeline, with more than 20 Telix
sponsored and investigator-led clinical trials spanning Phases 1 – 3.
Emerging Company of the Year: Fusetec
Established in 2017, Fusetec's medical technology is already revolutionising
medical training globally. Through its advanced additive manufacturing,
Fusetec's realistic, anatomically accurate bone, skin and muscle is used during
surgical training and reducing the need for medical students, residents and
surgeons to practice on real patients or extremely expensive cadavers. These
medical devices are made to order, and can be designed and manufactured to
simulate specific pathology. Currently available are models in orthopaedics,
otolaryngology, neurology and gynecology, with more surgical displines under
development.
Fusetec has secured global partnerships and opened a world-first 3D Advanced
Surgical Training Clinic in South Australia, creating 157 direct jobs in the
fields of research, production and administration; it expects to create an
additional 800 indirect jobs in South Australia within the supply chain,
medical tourism and higher education sectors.
AusBiotech Life Sciences Legacy Award: Dr Andrew Forrest AO and Nicola Forrest
AO
Dr Andrew Forrest AO and Nicola Forrest AO have demonstrated a deep commitment
to finding ethical and sustainable solutions to a range of global issues as
diverse as childhood cancer, ending modern slavery, and ocean conservation.
Among Australia's most active philanthropists and investors, they have invested
more than $2.6 billion since 2001 through the Minderoo Foundation which they
co-Chair.
Their commitment to improving equitable health outcomes and Australia's medical
and biotechnology ecosystem through their philanthropic and investment
activities, are proving transformational for the Australian life sciences
sector.
Minderoo's Collaborate Against Cancer initiative works with global partners to
overcome the greatest barriers to cancer prevention, diagnosis and treatment.
Through Minderoo, the Forrests are accelerating research and discovery of
breakthrough therapies to make world-class cancer care accessible to everyone,
no matter their address or background. In 2020, Minderoo mounted a pivotal
response to the COVID-19 pandemic to buffer Australia's diagnostic testing
capacity and personal protective equipment stockpiles in a time of critical
need.
Beyond their philanthropy, the Forrest family's Tarrarang Group has supported
Australian life science companies and recently launched Tenmile, a $250-million
venture capital fund dedicated to supporting innovators and companies to create
and nurture impactful health technology and biotech solutions. Tenmile seeks to
address unmet needs in healthcare and scale an Australian health science and
technology sector of global significance.
About AusBiotech
AusBiotech is Australia's biotechnology organisation, working on behalf of
members for more than 35 years to provide representation and services to
promote the global growth of Australian biotechnology. AusBiotech is a
well-connected network of over 3,000 members in the life sciences, including
therapeutics, medical technology (devices and diagnostics), food technology and
agricultural sectors.
source:AusBiotech
Image Attachments Links:
Link: http://asianetnews.net/view-attachment?attach-id=432531
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。